ArticleFrontiers in microbiology2018
Novel Activity of a Synthetic Decapeptide Against
Article in Frontiers in microbiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 28 citations in OpenAlex.
- Bacterial engineering for cancer therapy.Nature cancer · 2026Review
- Killer Peptide: an antibody-derived self-assembling peptide bridging antimicrobial and host-defense mechanisms.FEMS microbiology reviews · 2026Review
- Design, synthesis, and anti-Toxoplasma gondii evaluation of β-carboline derivatives.Parasites & vectors · 2025Article
- Killer Peptide-Containing Polyelectrolytic Nanocomplexes to FightPharmaceutics · 2025Article
- Antiprotozoal peptide prediction using machine learning with effective feature selection techniques.Heliyon · 2024Article
- Effect of the mitochondrial uncoupling agent BAM15 against the Toxoplasma gondii RH strain and Prugniaud strain.Parasites & vectors · 2024Article
- Biogenic selenium nanoparticles: trace element with promising anti-toxoplasma effect.Pathogens and global health · 2023Article
- Nanoformulation-Based 1,2,3-Triazole Sulfonamides for Anti-Tropical medicine and infectious disease · 2023Article
- Antimicrobial Peptides (AMPs): Potential Therapeutic Strategy against Trypanosomiases?Biomolecules · 2023Review
- Bioactive Peptides against Human Apicomplexan Parasites.Antibiotics (Basel, Switzerland) · 2022Review
- Activity of Two Antimicrobial Peptides againstAntibiotics (Basel, Switzerland) · 2021Article
- Article
- Review
- Anti-Infective Antibody-Derived Peptides Active against Endogenous and Exogenous Fungi.Microorganisms · 2021Review
- Myrislignan Induces Redox Imbalance and Activates Autophagy inFrontiers in cellular and infection microbiology · 2021Article
- Licarin-B Exhibits Activity Against theFrontiers in cell and developmental biology · 2021Article
- Antimicrobial peptides - Advances in development of therapeutic applications.Life sciences · 2020Review
- Antimalarial Agents as Therapeutic Tools Against Toxoplasmosis-A Short Bridge between Two Distant Illnesses.Molecules (Basel, Switzerland) · 2020Review
- Killer yeasts exert anti-plasmodial activities against the malaria parasite Plasmodium berghei in the vector mosquito Anopheles stephensi and in mice.Parasites & vectors · 2019Article
- Myrislignan Exhibits Activities AgainstFrontiers in microbiology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The killer peptide KP is a synthetic decapeptide derived from the sequence of the variable region of a recombinant yeast killer toxin-like microbicidal single-chain antibody. KP proved to exert significant activities against diverse microbial and viral pathogens through different mechanisms of action, but little is known of its effect on apicomplexan protozoa. The aim of the present study was to evaluate the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.